Wikipedia

Henri Termeer

Henri A. Termeer (February 28, 1946 – May 12, 2017)[5] was a Dutch biotechnology executive and entrepreneur who is considered a pioneer[6] in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme.[7] Termeer created a business model[6] adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders[6] known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness[8] nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni.[9] Termeer was "connected to 311 board members in 17 different organizations across 20 different industries"[8]: 296 [1][10] He has the legacy of being the "longest-serving CEO in the biotechnology industry.[6]

Henri Termeer
Termeer 2012
Born(1946-02-28)February 28, 1946[1]
Tilburg, Netherlands[1]
DiedMay 12, 2017(2017-05-12) (aged 71)
Marblehead, Massachusetts, U.S.
Alma materErasmus University
Occupation(s)Executive
Biotechnology entrepreneur
Board member ofVerastem
Genzyme (1983–2011)
Federal Reserve Bank of Boston
ABIOMED Inc
Massachusetts Institute of Technology Corporation
Massachusetts General Hospital
Partners HealthCare System[2][3]
Fellows of Harvard Medical School
Pharmaceutical Research and Manufacturers of America[2]Biotechnology Industry Organization[4]
Moderna Therapeutics (2013-)
SpouseBelinda Termeer
ChildrenNicholas, Adriana
Parent(s)Jacques and Mary (Van Gorp)

He was an "advocate for the Massachusetts biotech industry." "To generate revenues to fund the research, Termeer entered into a number of side ventures including a chemical supplies business, a genetic counseling."[11]: 344 

Termeer was named as one of the top fifty leaders of thought in orphan drugs and rare diseases in a list published by Terrapin for the World Orphan Drug Congress which included "eminent personalities that have advanced rare disease research."[12] The congress described him as an "inspiration and pioneer", many of whose protégés have gone on to lead other successful companies in the rare disease and biotech sector.[12]

Education

edit

Termeer "studied economics at the Economische Hogeschool, Erasmus University, The Netherlands.[1] In 1973 he completed his MBA at Darden School at the University of Virginia.[1] He received an honorary Doctor of Science from the University of Massachusetts.

Norvic

edit

From 1969 to 1971 Termeer was a manager in management services in Norwich, United Kingdom, at the Norvic Company, a show company.

Baxter International

edit

He began his career in the medical and healthcare product industry in 1973 when he started working as manager of international product planning for Deerfield, Illinois-based Travenol Laboratories Inc now Baxter. From 1975 to 1976 he was Baxter's international marketing manager. From 1976 to 1979 he was general manager for Travenol GMBH in Munich.

From 1979 to 1981 he was executive vice president of the Hyland Therapeutics division of Baxter Travenol in Glendale, California.[10] In the United States, plasma donors were paid for their time as the time commitment for regular donors is over 200 hours per year. Standards for donating plasma are set by the U.S. Food and Drug Administration (FDA).[13] Almost all plasmapheresis in the US is performed by automated methods such as the Plasma Collection System (PCS2) made by Haemonetics or the Autopheresis-C (Auto-C) made by Fenwal, Inc., a former division of Baxter International. Termeer explained, "This was the beginning of biotechnology. You took plasma and pulled it apart, fractionated it. Hyland sold Factor VIII, Factor IX, immunoglobulins, and albumin. The plasma was collected through plasmapheresis performed at collection centers all around the country. They paid people for plasma. They returned the red cells and paid for the plasma ... There were ethical concerns about the payments. Very vulnerable people were being paid."[1] At that time Baxter was developing tests for Chagas disease which was very prevalent in Latin America, based on feedback indicating that it would be a big market. Termeer was sent to South America to "figure out a way to set up the connections" which was how Baxter operated. After meeting with the military and with the Center for Disease Control he called off the project as unprofitable.[1]

Back in Chicago he was Baxter's International Marketing Manager for several years with the "Artificial Organs Division—artificial kidneys, dialysis equipment, heart/lung machines, stuff like that.[1] This was a period of pioneering work in dialysis and in the development of heart and lung machines for open heart surgeries.[1]

Monica Higgins profiled Termeer as one of the alumni of the Baxter biopharmaceutical industryfirm, the 'Baxter boys'—who produced many of the leaders of the burgeoning biopharmaceutical industry. By 2004 Henri Termeer's leadership at Genzyme was considered "by many industry observers as exemplary and the firm, Genzyme, has often been seen as a role model for other firms in the industry."[14] Higgins noted in 2004 that at that time, [t]he size and extent of Baxter's influence overall [was] difficult to ascertain since the biotechnology industry, with eight- to ten-year product development cycles, [was] still in its relative infancy."[14][15]

In December 2011, the non-partisan organization Public Campaign criticized Baxter for spending $10.45 million on lobbying and not paying any taxes during 2008–2010, instead getting $66 million in tax rebates, despite making a profit of $926 million.[16]

Genzyme

edit
Main article: Genzyme

According to the Boston Globe staff writer Robert Weisman,[17]

In the formative years of biotechnology, Genzyme was the industry's Apple, blazing a pathway for creating protein-based treatments for rare diseases."

In 1983 Termeer became chairman, CEO and president of Genzyme, a then two-year old start-up biotechnology company, located in Cambridge, Massachusetts.[1] At that time,[18]

Genzyme was just these professors from MIT and myself and some venture capitalists."

— Termeer 2011

In 1985 he was appointed as their CEO. By 1988 he was chairman of Genzyme.[1] During those years he held positions at Genzyme in Genzyme Tissue Repair, Strategic Planning & Capital Allocation Committee and Member of Risk Oversight Committee, Genzyme Oncology.[10]

When Genzyme needed a manufacturing facility, Termeer deliberately chose to remain in Massachusetts and use local contractors instead of using the pharmaceuticals cluster in the New Jersey and Philadelphia areas and their more specialized engineering firms. "Massachusetts is home to a vibrant biotechnology cluster, which draws on the region's strong universities, medical centers, and venture capital firms."[19]

Harvard Business School professor, Michael E. Porter, a leading authority on competitive strategy and the competitiveness taught courses to newly appointed CEOs of very large corporations. Porter described Termeer's strategy as a cluster, the new economics of competition with all members benefiting from "a strong base of supporting functions and institutions."[19] Under Termeer's leadership, Genzyme built a "critical mass" for its "cluster," in Massachusetts, a group of institutions that achieved unusual competitive success in the life sciences industry or biotechnology.[19]

Specialty pharmacy

edit

In 2005 Genzyme chose the specialty pharmacy division of PharmaCare, one of the largest pharmaceutical benefit management companies, as national network provider for Thyrogen, Genzyme's specialty drug.[20]

Cerezyme and Gaucher's disease

edit

In 1991 the first version of Genzyme's orphan drug Alglucerase (brand name Ceredase), the only treatment for Gaucher's disease,[21] was approved by the FDA.[22]

Termeer explained in a 2005 interview for The Wall Street Journal that in 1991 one treatment of Cerezyme for one patient took 22,000 placentas annually to manufacture, a difficult and expensive procedure.[23] According to the Congressional Office of Technology Assessment cerezyme cost $1.90 per unit including the cost of manufacturing, marketing and distribution. Genzyme charged $3.50 a unit.[23] Imiglucerase was granted orphan drug status in the US, Australia, and Japan.[24][25][26]

By 1994 Genzyme had a new version of Cerezyme produced in genetically engineered cells in a process that was easier and cheaper.[23] Although imiglucerase costs only less than 37 cents to manufacture, Genzyme charges $3.70 per unit making a 90% profit. The high price of the medication is part of Genzyme's business strategy in order for the biotech firm to undertake research and development for other drugs and to allow them to fund programs that distribute a small portion of production for free.[23] So instead of lowering the price Termeer "decided to use the extra revenue to give additional Cerezyme away free in countries that can't afford to pay the high price. He said Genzyme gives away about 10% of the drug it produces." In order to ensure patients had access to Cerezyme, by 2005 Genzyme had hired 34 people to help patients acquire insurance plans that would cover the cost of their drugs.[23] By 2005 there was still no competition for the drug and with patients desperate for a therapy, most insurers were willing to pay.[23] Genzyme used the profits "to bring new treatments to market for two other rare diseases. It has purchased many small companies to expand into a diversified drug company with cancer, kidney disease and diagnostic products, among others."[23]

By 2005 although Cerezyme cost the average patient (including babies) $200,000 a year, it could cost a single adult patient as much as $520,000 a year even though it cost Genzyme less than $52,000 to manufacture.[23] In 2005 there were only about 4,500 patients on Cerezyme.[23]

Pompe disease

edit

In 1998, two of Crowley's children, Megan and Patrick, were diagnosed with a severe neuromuscular disorder, glycogen storage disease type II, also called Pompe's disease. In the face of the children's deteriorating health, the family moved to Princeton, New Jersey, to be close to doctors specializing in the disease.[27] Crowley worked at Bristol-Myers Squibb, where he held a number of management positions. Frustrated with the slow pace of research on Pompe's disease, Crowley left Bristol-Myers Squibb in March 2000, and took a position as CEO of Novazyme Pharmaceuticals, a biotechnology research company located in Oklahoma City founded by Dr.William Canfield, that was conducting research on a new experimental treatment for the disease.[28]

Biotech executive john Crowley, whose two children were diagnosed in 1998 with Pompe's disease, had been a major force behind the search for a cure. By 2001 Genzyme when acquired Novazyme, Termeer put Crowley in charge Genzyme's global Pompe program, the largest R&D effort in the company's history, from September 2001 until December 2002. At that time Genzyme was considered to be the world's third largest biotechnology company,[29][30] Genzyme's work eventually bore fruit and in January 2003, Crowley's children received the enzyme replacement therapy for Pompe disease developed by Genzyme. Crowley credits the experimental trial with saving his children's lives.[29] The acquisition of Novazyme by Genzyme, and Crowley's fight to cure Pompe's Disease, was documented in the Harvard Business School Case Study, Novazyme: A Father's Love.[31][32]

According to Higgins by 2004 Henri Termeer's leadership at Genzyme was celebrated by a number of biotech industry observers as exemplary. Genzyme, in 2004 was seen as a role model for other biotechnology firms.[14]

According to The Wall Street Journal, in 2004 Termeer earned a combined salary and bonus of $3 million. He also had "options valued at between $12.6 million and $32 million in 10 years, based on appreciation of the company's stock of between 5% and 10% a year, according to the company's proxy."[23]

In 2007 Genzyme acquired Bioenvision and the rights to the North American market for clofarabine,[33] (brand name Clofarex), designated by the Food and Drug Administration (FDA) as an orphan drug[34]

In 2007 Termeer as CEO earned a salary of $2.5 million, and non-cash compensation worth $129 million.[35]

From 2007 to 2008 under Termeer as CEO, Genzyme spent $2.8 million on lobbying. In 2009 alone, Genzyme had 10 different organizations with a total of 49 lobbyists working on its behalf.[36]

In 1981, before Termeer had joined Genzyme, it was a small firm that "employed 14 people in an office in Chinatown."[37] By 2006 Genzyme with Termeer as CEO Genzyme became a biotech powerhouse with a "payroll of more than 8,000 in 70 offices and plants worldwide, making it the third-largest company of its kind."[37] In 2004 "Termeer was the area's highest-paid CEO" in 2004, with a "total compensation package worth at least $37.9 million."[37] He was 42nd in the 2006 list of Boston's wealthiest with a networth of $342 million.[37]

In June 2009 Genzyme experienced a manufacturing disaster after contamination with Vesivirus 2117 at their Allston, Massachusetts plant that resulted in shortages of Genzyme drugs including Cerezyme.[38][39] Patients and shareholders depicted Genzyme corporate behaviour as irresponsible and arrogant.[39] Genzyme was fined $175 million by the FDA for manufacturing deficiencies.[39] Genzymes's competitors benefited[39] and Genzyme stocks fell. As a result, 2011 Genzyme was acquired by Sanofi in an hostile takeover in October 2011—engineered in part by then-CEO of Sanofi, Christopher Viehbacher—[40]: 219  for more than $20 billion. Termeer retired.[9][39]

When Termeer left Genzyme his payout was valued at about $138 million,[6][39] making him "one of the biggest all-time winners in biotech."[6]

Institutional and advisory work

edit

In 1993, Termeer helped establish the Biotechnology Industry Organization (BIO), and joined the board of directors. The BIO was formed through the merger of the Association of Biotechnology Companies (ABC), an association of smaller start-ups and their business support network, and the Industrial Biotechnology Association (IBA) an organization for the larger biotech firms. Following the election of President Bill Clinton in 1992, Termeer was concerned about potential health-care and FDA reform, and wanted the biotechnology industry to speak with one voice.[41] By engaging and including patient groups, religious groups, etc.[41] the BIO successfully lobbied in favour of the Food and Drug Administration Modernization Act of 1997 which provided criteria for "fast-track drug development, allowed some drug approvals based on one pivotal trial, provided easier patient access to experimental drugs and devices, and renewed the Prescription Drug User Fee program".[41]

In 2002 Termeer was involved in the establishment of the New England Healthcare Institute (NEHI), a "nonprofit, applied research health policy organization" composed of senior healthcare experts and executives.[42][43] NEHI members include biotech and pharmaceutical companies, academic health centers, hospitals, medical device companies, employers, payers, patient groups, and others.[43] Termeer was a Chairman Emeritus of the New England Healthcare Institute.

In 2008 Governor Deval Patrick appointed Termeer to the Massachusetts Council of Economic Advisors.[42]

Private equity

edit

Erik Gordon from Ann Arbor, a University of Michigan business professor, remarked on Termeer's success "selling some of the world's most expensive medicines, priced from $200,000 to $300,000 a year" and suggested that following his retirement from Genzyme in 2011, Termeer may be hired by private-equity firms to "pitch deals. Ex-Wyeth CEO Bob Essner became a senior advisor with the Carlyle Group—a "behemoth in private-equity"— on the firm's health-care investments.[44] Ex-CEO Fred Hassan of Schering-Plough Corporation has been working with private-equity firm Warburg Pincus LLC.[44]

Henri is the guy you send out as your sales guy to get your real guys in the door. For an investment firm seeking biotech business, "he would be a good guy to have. The CEO of a midmarket biotech company, they'll take a Henri Termeer call. They would all love to be Henri Termeer one day."

— Erik Gordon 2011

AVEO oncology

edit

By 2012 Termeer was "chairman of cancer drug specialists Aveo Oncology ($AVEO).[9]

Prosensa

edit

In 2012 Termeer became strategic advisor for Prosensa, a venture-backed biotech[9] to provide advice on corporate strategy and to lobby for Protensa, bringing his "experience in building Genzyme into a world leader in rare diseases." Prosensa's lead compound, a RNA therapy, 051, for an orphan disease known as Duchenne muscular dystrophy (DMD), is being developed by pharmaceutical giant, GlaxoSmithKline (GSK).[9] GSK, which also makes major investments in rare diseases and orphan drugs, licensed 051 in 2009 for "$25 million upfront and another $655 million in milestones."[45] "Prosensa has a technology that could provide an array of RNA therapies for different variants of DMD, which affects about 1 in 3,500 male births and causes muscle wasting that leads to premature death."[9] In 2012 Prosensa was listed by the industry news monitor Fierce Biotech's Fierce 15 as one of their top choices of pharmaceutical firms. Fierce Biotech covers biotechnology news including biopharma deals and clinical trials.[45]

When Prosensa was founded in 2002 in Leiden, Netherlands with Hans Schikan as CEO, it was sustained for several years by patient groups—like Charlie's Funds— a non-profit foundation which provided funds for scientific research on DMD.[46] Charlie's fund received over a million dollars from the documentary, Darius Goes West: The Roll of his Life a documentary about a young DMD patient, Darius Weems' 2005 fund-raising road-trip across the United States. [47] When Prosensa CEO Hans Schikan served at Genzyme, he was "responsible for the global marketing and strategy development of the genetic disease portfolio of orphan medicinal products, which includes the first treatment for Pompe disease." Prosensa, like Genzyme focuses on rare inherited diseases.[9]

By 2012 Propensa had accumulated €55 million in venture capital and had €47 million in the bank. Prosensa's experience in fundraising over the years has provided a model for other rare disease startups."[45]

New Enterprise Associates contributed to Prosensa as its first entry into the European market.[45][48]

Prosensa employs over 80 people. "The company attracted prominent life science ventures capitalists, including Life Science Partners, Abingworth and New Enterprise Associates (NEA), who led a E23m round last January, bringing David Mott, General Partner of NEA and formerly a key executive with MedImmune to the Supervisory Board. Also added to this Supervisory Board in recent months has been Henri Termeer, former chairman and CEO of Genzyme for some three decades."[49]

ProQR 2014

edit

The Dutch biotech startup ProQR Therapeutics BV, a start-up from Leiden, "licensed a compound from Boston scientists to develop a treatment" for cystic fibrosis focusing on the role of messenger RNA in cystic fibrosis. In 2013 ProQR's CEO Daniel de Boer, whose three-year-old son suffers from cystic fibrosis was introduced to Termeer in Boston by Dutch biotechnology leader Dinko Valerio.[50] Termeer and Valerio are part of a group of well-connected biotech executives financially backing the Dutch biotech ProQR which was focused on the role of messenger RNA in cystic fibrosis and has now pivoted to inherited retinal diseases including Leber congenital amaurosis, Usher syndrome and retinitis pigmentosa. ProQR laid out its proposed terms for a $75 million IPO. ProQR planned "to sell 6.3 million shares at $11 to $13 a share." ProQR is competing with Vertex whose lead drug would serve the same patient population. Termeer and his group "expect to take the program all the way through to commercialization."[51]

Moderna Therapeutics

edit

In April 2013 Termeer joined the board of directors of Moderna Therapeutics, a Cambridge-based biotech company that was developing a platform technology for delivery of mRNA.[52][53][54] The company creates synthetic mRNA that can be injected into patients to help them create their own therapies. By December 2012 Moderna Therapeutics received $40 million "financing led by Flagship Ventures and a consortium of private investors."[52]

CANbridge

edit

In September 2013 China's CANbridge, which commercializes Western clinical stage pharmaceutical products in China, appointed Termeer as Chief Advisor of their Life Sciences Advisory Board.[55]

Mentorship

edit

In 2015, from his home office in Marblehead, Massachusetts overlooking Marblehead Harbor, Termeer continued to mentor former Genzyme colleagues who are now CEOs of about two dozen smaller companies.[17] Among this group of elite biotech entrepreneurs — the "Genzyme diaspora"— are Geoff McDonough, now CEO of Generation Bio, Gail Maderis, who runs biotechnology firms and an industry trade group in the San Francisco Bay area, Tom Mathers, CEO at CoLucid Pharmaceuticals Inc, Jeff Albers has a Cambridge-based startup, Blueprint Medicines Corporation and Greg Madison, CEO of New York's Keryx Biopharmaceuticals Inc.[17]

Awards

edit
 
Memorial in Henri A. Termeer Square in East Cambridge

Global Genes RARE Project Champions of Hope

edit

In 2012 Termeer received the Lifetime Achievement Award from Nicole Boice, founder and CEO, Global Genes R.A.R.E Project. He was honoured for leading Genzyme for nearly 30 years and helping "to establish Massachusetts as a major center of industrial biotech research and development," for "spearheading the development of rare disease treatments at a time when other pharmaceutical companies were focusing on drugs for much larger patient populations."[58]

Academic

edit

Other affiliations

edit

Termeer was "connected to 311 board members in 17 different organizations across 20 different industries"[10] including AutoImmune Inc., Diacrin, Inc., rEVO Biologics, Inc., Allergan Inc., Genzyme Corporation, Tekla Life Sciences Investors, AVEO Pharmaceuticals, Partners HealthCare System, Federal Reserve Bank of Boston, Biotechnology Industry Organization, Erasmus University, Capital Royalty, Federal Reserve Bank of Atlanta, Colgate W. Darden Graduate School of Business Administration, Longwood Founders Management, Verastem, Moderna Therapeutics, ProQR Therapeutics, CANbridge Life Sciences and the Fellows of Harvard Medical School Termeer serves on their board of directors.[2][59]

Lysosomal Therapeutics

edit

Termeer provided financial backing for Lysosomal Therapeutics or N.V.Lysosomal Therapeutics Inc., a fledgling biotech firm in Boston, developing a treatment for Parkinson's and other neurodegenerative diseases. According to Bloomberg Termeer is the founder of Lysosomal Therapeutics.[10] Termeer was mentoring Lysosomal Therapeutics CEO Dimitri Krainc, who is a neurologist at Massachusetts General Hospital and is originally from Slovenia. According to Krainc, he and Termeer were in "contact by e-mail, phone, or in person weekly. ... It's fun to meet with Henri. He listens. He's got incredibly good judgment. And he's very focused on the patients."[50]

Philanthropy

edit

Massachusetts General Hospital

edit

Termeer $10 million donation.[9] funds research at the Henri and Belinda Termeer Center for Targeted Therapies at the Massachusetts General Hospital Cancer Center[9] where patients with early and advanced stage cancers enroll in "its fast-growing portfolio of Phase I, Phase II and Phase III clinical trials."[60] Termeer was on the board of directors of the MGH and had served on numerous committees with Peter Slavin, Hospital director.[61]

In 2011 Termeer Cathy Minehan, and Chad Gifford— fellow Partners HealthCare Board Members— co-chaired the Massachusetts General Hospital bicentennial. The gala, with 1,000 in attendance, also served as a fundraiser, raising approximately $1 million.[62]

References

edit
  1. ^ a b c d e f g h i j k Gavin Rynne; Mark Jones, eds. (2013), Conversations with Henri Termeer (PDF), The Life Sciences Foundation Oral History Program, San Francisco, archived from the original (PDF) on July 21, 2015, retrieved July 7, 2015{{citation}}: CS1 maint: location missing publisher (link) Oral history conducted by Ted Everson, Jennifer Dionisio, Pei Koay, and Arnold Thackray, May 23, December 7, 2006, August 2, 2007, December 18, 2008 & September 30, 2011
  2. ^ a b c "Board of Directors", Verastem, 2015, retrieved July 9, 2015
  3. ^ "Board of Directors", Partners HealthCare System, archived from the original on July 12, 2015, retrieved September 24, 2015
  4. ^ Terrapinn Holdings Ltd (2015). Mr Henri Termeer: Chief Executive Officer, Former Genzyme. Orphan Drug Congress. Retrieved September 27, 2015.
  5. ^ Marquard, Bryan; Weisman, Robert (May 13, 2017). "Henri A. Termeer, key biotech leader who built Genzyme into an industry giant, dies at 71". The Boston Globe. Archived from the original on May 15, 2017. Retrieved May 13, 2017.
  6. ^ a b c d e f Meg Tirrell (February 16, 2011), Genzyme's Termeer May Follow Health Care CEO Path to Private Equity Firms, Bloomberg, retrieved July 17, 2015
  7. ^ Genzyme's Termeer, Biotechnology Pioneer, May Sell, Bloomberg, September 1, 2010, retrieved July 17, 2015
  8. ^ a b Porter, Kelley; Kjersten Bunker Whittington; Walter W. Powell (2005). "The institutional embeddedness of high-tech regions: relational foundations of the Boston biotechnology community". In Stefano Breschi; Franco Malerba (eds.). Clusters, networks, and innovation. Vol. 261.
  9. ^ a b c d e f g h i Ryan McBride (December 13, 2012), "Ex-Genzyme CEO Termeer returns to his roots at biotech Prosensa", Fierce Biotech, retrieved July 8, 2015
  10. ^ a b c d e Verastem Inc (VSTM:NASDAQ GM), Bloomberg, August 30, 2023
  11. ^ Hill, Charles; Jones, Gareth; Schilling, Melissa (2014), Strategic Management: Theory & Cases: An Integrated Approach, Cengage Learning
  12. ^ a b "The top 50 thought-leaders in orphan drugs and rare disease" (PDF), World Orphan Drug Congress USA, 2013, retrieved July 20, 2015
  13. ^ FDA > CDRH > CFR Title 21 Database Search
  14. ^ a b c Monica C. Higgins (March 2005), Career Imprints: Creating Leaders Across An Industry, Wiley, p. 416, ISBN 978-0-7879-7751-1
  15. ^ Henri A. Termeer (April 2014). "A Biotechnology Entrepreneur's Story: Advice to Future Entrepreneurs". In Craig Shimasaki (ed.). Biotechnology Entrepreneurship: Starting, Managing, and Leading Biotech. Academic Press. pp. 15–20. ISBN 978-0-12-404730-3.
  16. ^ Portero, Ashley. "30 Major U.S. Corporations Paid More to Lobby Congress Than Income Taxes, 2008–2010". International Business Times. Archived from the original on January 7, 2012. Retrieved December 26, 2011.
  17. ^ a b c Robert Weisman (July 12, 2015), How Genzyme became a source of biotech executives, The Boston Globe, retrieved July 17, 2015
  18. ^ Henri A. Termeer (April 10, 2011), "Going out on top", Boston.com, The Boston Globe, retrieved July 17, 2015 as told to Scott Helman
  19. ^ a b c Michael E. Porter (December 1998), "Clusters and the New Economics of Competition", Harvard Business Review
  20. ^ "PharmaCare Included in Genzyme's Thyrogen(R) Distribution Network". CVS Health. April 21, 2005. Retrieved September 24, 2015.
  21. ^ Deegan PB, Cox TM (2012). "Imiglucerase in the treatment of Gaucher disease: a history and perspective". Drug Design, Development and Therapy. 6: 81–106. doi:10.2147/DDDT.S14395. PMC 3340106. PMID 22563238.
  22. ^ World Health Organization. Regulatory Matters WHO Drug Information 5:3 1991. p 123
  23. ^ a b c d e f g h i j Geeta Anand (November 2005), "Why Genzyme Can Charge So Much for Cerezyme", The Wall Street Journal, retrieved July 9, 2015
  24. ^ "Imiglucerase on Orpha.net: The portal for rare diseases and orphan drugs".
  25. ^ Weinreb NJ (August 2008). "Imiglucerase and its use for the treatment of Gaucher's disease". Expert Opinion on Pharmacotherapy. 9 (11): 1987–2000. doi:10.1517/14656566.9.11.1987. PMID 18627336. S2CID 72183308.
  26. ^ Starzyk K, Richards S, Yee J, Smith SE, Kingma W (February 2007). "The long-term international safety experience of imiglucerase therapy for Gaucher disease". Molecular Genetics and Metabolism. 90 (2): 157–63. doi:10.1016/j.ymgme.2006.09.003. PMID 17079176.
  27. ^ Edelstein, Jeff. "Look Who's Talking: John Crowley, dad, entrepreneur, and subject of the upcoming film Extraordinary Measures" Archived March 14, 2012, at the Wayback Machine, The Trentonian, January 11, 2010. Accessed February 17, 2011. "Princeton's Crowley family, from left, Megan, Aileen, John, Patrick, and John Jr. John Crowley, a Princeton Township resident, is the father of two children with Pompe disease."
  28. ^ "John Crowley On The Today Show 2001". Youtube.com, September 2001. Accessed June 16, 2008.
  29. ^ a b Crowley, John. "To Save the Children". Notre Dame Lawyer, Spring 2007. Accessed April 4, 2008.
  30. ^ Amicus Therapeutics, Inc. Executive Profile[dead link‍], BusinessWeek. Accessed April 4, 2008.
  31. ^ "A Father's Love: Novazyme Pharmaceuticals, Inc. ". Harvard.edu, October 2002. Accessed June 14, 2011.
  32. ^ "Journey of the Heart". PharmaVoice.com, January 2009. Accessed April 8, 2009.
  33. ^ "Genzyme Claims Victory in Prolonged Bid for Bioenvision". International Herald Tribune (France). Associated Press. October 22, 2007. Retrieved November 10, 2007.
  34. ^ "Clofarabine", Drugs in R&D, 5 (4): 213–7, 2004, doi:10.2165/00126839-200405040-00005, PMID 15230627, S2CID 261073158
  35. ^ Forbes (December 2007). "Henri Termeer Profile". Henri Teemer profile. Archived from the original on December 28, 2001. Retrieved July 10, 2008.
  36. ^ Client Profile: Summary, OpenSecrets, 2008
  37. ^ a b c d Francis Storrs (March 2006), The 50 Wealthiest Bostonians, Boston Magazine, archived from the original on November 28, 2016, retrieved July 8, 2015
  38. ^ Erin Ailworth; Robert Weisman (June 17, 2009). "Virus shuts Genzyme plant, holds up drugs for 8,000". The Boston Globe.
  39. ^ a b c d e f Luke Timmerman (May 13, 2013), "Henri Termeer on Startups, Drug Prices, Getting Older (Part 1)", Xconomy, retrieved July 9, 2015
  40. ^ Nicholas Wright Gillham (2011). Genes, Chromosomes, and Disease: From Simple Traits, to Complex Traits. FT Press Science. ISBN 978-0137075447.
  41. ^ a b c Henri A. Termeer Genzyme, 1995–1997, Washington, D.C.: Biotechnology Industry Organization, archived from the original on September 25, 2015, retrieved July 8, 2015
  42. ^ a b "About", Verastem
  43. ^ a b Joshua Boger (May 7, 2007), Building on a System of Outreach, Collaboration, The Boston Globe, retrieved July 8, 2015
  44. ^ a b James A. White (April 8, 2010), "Ex-Wyeth CEO Bob Essner Moves to Private Equity's Carlyle Group", The Wall Street Journal, retrieved July 17, 2015
  45. ^ a b c d "Prosensa – 2012 Fierce 15", Fierce Biotech, September 19, 2012, retrieved July 8, 2015
  46. ^ Plasse, Sabina Dana (January 22, 2010). "Facebook challenge offers $1 million for research". Idaho Mountain Express. mtexpress.com. Archived from the original on January 28, 2010. Retrieved June 16, 2010.
  47. ^ Myers, Jack (February 10, 2009). "TED Conference 2009: Inspiration and an Uplifting Spirit of Hope for Future Generations". The Huffington Post. Retrieved June 17, 2010.
  48. ^ "New Enterprise Associates Closes $2.6 Billion In One Of Largest Venture Funds Ever", Forbes, July 25, 2012, retrieved July 8, 2015
  49. ^ "Prosensa & GSK pool resources to drive Drisapersen in Duchenne". February 26, 2013.
  50. ^ a b Robert Weisman (January 20, 2013), Henri Termeer isn't exactly settling into retirement: Not content to rest on his laurels, the former Genzyme chief stays busy as a tireless advocate for the Massachusetts biotech industry, San Francisco: The Boston Globe, retrieved July 8, 2015
  51. ^ John Carrol (September 9, 2014), "Termeer-backed ProQR lays out terms for $75M IPO", Fierce Biotech
  52. ^ a b Catherine Shaffer (December 6, 2013). "Moderna Makes Entrance with $40M Round for mRNA Work". BioWorld. Retrieved December 11, 2013.
  53. ^ Henri A. Termeer Joins Moderna Therapeutics Board of Directors, Cambridge, Mass., April 30, 2013, archived from the original on July 8, 2015, retrieved July 8, 2015{{citation}}: CS1 maint: location missing publisher (link)
  54. ^ Zangi L, Lui KO, von Gise A, Ma Q, Ebina W, Ptaszek LM, Später D, Xu H, Tabebordbar M, Gorbatov R, Sena B, Nahrendorf M, Briscoe DM, Li RA, Wagers AJ, Rossi DJ, Pu WT, Chien KR (September 8, 2013). "Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction". Nature Biotechnology. 31 (10): 898–907. doi:10.1038/nbt.2682. PMC 4058317. PMID 24013197.
  55. ^ CANbridge Life Sciences Appoints Former Genzyme CEO, Henri Termeer, to Advisory Board, Beijing: Business Wire, September 26, 2013, retrieved July 8, 2015[permanent dead link‍]
  56. ^ "Biotechnology Heritage Award". Science History Institute. May 31, 2016. Retrieved March 22, 2018.
  57. ^ Krughoff, Tracy (June 15, 2008). "Henri A. Termeer to Receive 2008 Biotechnology Heritage Award". BIO. Retrieved February 5, 2014.
  58. ^ "Global Genes and R.A.R.E. Project Announce Tribute to Champions of Hope™ Gala to Honor Rare and Genetic Disease Pioneers, Innovators and Advocates", Global Genes, Dana Point, California, June 27, 2012, retrieved July 9, 2015
  59. ^ "Board of Directors", Fellows of Harvard Medical School
  60. ^ "Treatment Programs", Massachusetts General Hospital
  61. ^ Termeer Center Opening Reception, October 2, 2012, retrieved July 9, 2015Talks by MGH President Dr. Peter Slavin, Mass General Cancer Center Director Dr. Daniel Haber, Termeer Center Director Dr. Keith Flaherty, patient John Murphy and donor Henri Termeer
  62. ^ Kissinger, Gifford, Termeer attend MGH bicentennial, The Boston Globe, September 19, 2011, retrieved July 16, 2015
Retrieved from "https://en.wiki.x.io/w/index.php?title=Henri_Termeer&oldid=1237310308"